A Case of Vitiligo Combined With Systemic Lupus Erythematosus Treated With Tofacitinib

March 2024 in “ Clinical, cosmetic and investigational dermatology ”

Qingxia Lin, Jinrong Zhu, Xing‐Hua Gao

vitiligo systemic lupus erythematosus tofacitinib JAK inhibitor autoimmune diseases SLE

Studysummary In this report, a patient with vitiligo and systemic lupus erythematosus achieved complete skin repigmentation after 30 days of treatment with the oral JAK inhibitor tofacitinib, with no adverse reactions, suggesting its efficacy and safety as a potential treatment for vitiligo with coexisting autoimmune conditions. Our plain-language summary of this paper — not a Tressless recommendation.

This report discusses a unique case of a patient with vitiligo and systemic lupus erythematosus (SLE) who achieved complete repigmentation of the white macular rash after a 30-day treatment with tofacitinib, an oral JAK inhibitor. The treatment was effective and did not result in any adverse drug reactions, suggesting that JAK inhibitors like tofacitinib could be a promising new treatment option for vitiligo, especially in patients with concurrent autoimmune diseases.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.